Late-Stage Drugs Are Hotbed for Co-Development and Licensing Deals

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--

The transition from discovery and development to drug commercialization requires an entirely different set of skills, as both large and small pharmaceutical and biotech companies have found. And the costs of successfully planning and executing a global drug launch must now cover more regions and more functional groups than ever before, according to findings from consulting firm Cutting Edge Information.

Complex pieces of the global launch puzzle such as regulatory submission, managed markets planning, and launch sequencing must be coordinated carefully. Each piece has a large impact on initial market reception and can drag down or drive up revenue results. These commercial steps require expertise quite different from earlier clinical trial phases; trying to shoehorn clinical experience into commercial needs invites disaster.

Licensing and co-development deals can bridge the gap. Cutting Edge Informations recent study, Business Development and Licensing: Strengthening Pipelines and Managing Relationships, profiles how a development-oriented company with a promising compound primed for market, but without commercialization infrastructure, can leverage another companys experience to continue preparing the new product for launch.

Collaborating with a company that has deep experience with regulatory submission and launch in major and emerging markets will save time and reduce the risk of making mistakes, said Adam Bianchi, chief operating officer at Cutting Edge Information. The resources required to take a compound from Phase I into Phase III clinical trials are quite different from those needed for successful submission and launch. Even a perfect focus on clinical will not translate to the commercial side without adding substantial expertise and budget.

Business Development and Licensing: Strengthening Pipelines and Managing Relationships can be found at http://www.cuttingedgeinfo.com/research/portfolio-management/business-development/. Executive findings include:

For more information about building and maintaining a top-notch pharmaceutical business development and licensing team, contact Eric Bolesh at +1 919-403-6583.

See original here:
Late-Stage Drugs Are Hotbed for Co-Development and Licensing Deals